Debiopharm in the news
Developing prescription drugs
Tamtam found 20 recent articles about Debiopharm.
- Peptron launches next-generation ADC research collaboration with Debiopharm
Peptron is collaborating with Debiopharm to develop next-generation cancer treatments by combining a MUC1-targeting antibody with a flexible ADC linker platform.
- Peptone Signs Joint Research Agreement with Swiss Debiopharm for ADC Development
Debiopharm is partnering with Peptone to develop next-generation antibody-drug conjugates using its proprietary MultiLINK platform and the PAb001 antibody.
- Peptron Partners with Switzerland's Debiopharm to Develop Next-Generation ADC
Peptron and Debiopharm are collaborating to develop next-generation cancer treatments by combining specialized antibodies with dual-payload ADC technology.
- Peptron launches next-generation ADC research collaboration with Debiopharm
Peptron and Debiopharm are collaborating to develop MUC1-targeting antibody-drug conjugates using the MultiLINK platform for solid tumor treatments.
- Peptone Signs Joint Research Agreement with Swiss Debiopharm for ADC Development
Debiopharm is partnering with Peptone to develop next-generation cancer therapies by combining a MUC1-targeting antibody with a proprietary ADC linker-payload platform.
- Peptron Partners with Switzerland's Debiopharm to Develop Next-Generation ADC
Peptron and Debiopharm are collaborating to develop new cancer treatments by combining PAb001 antibodies with the MultiLINK ADC platform.
- Peptone Signs Joint Research Agreement with Swiss Debiopharm for ADC Development
Peptone and Debiopharm have signed a joint research agreement to develop next-generation antibody-drug conjugates using Peptone's PAb001 antibody and Debiopharm's MultiLINK™ platform.
- Genome & Company Eyes Big Pharma Licensing as Partners Expand Trials
Genome & Company's partners are expanding clinical trials for licensed candidates while the firm pursues new high-value technology transfers for its ADC pipeline.
- Acromegaly Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Crinetics, Camurus, Chiesi, Debiopharm International SA, AstraZeneca, Marea Therapeutics
The global acromegaly market is expanding due to new drug approvals and rising diagnosis rates across the United States, Europe, and Japan.
- Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer
FDA granted Fast Track designation to a combination therapy for platinum-resistant ovarian cancer following positive Phase I data.
- Debiopharm’s lunresertib and zedoresertib combo picks up FDA Fast Track status for ovarian cancer
Debiopharm's combination therapy of lunresertib and zedoresertib received FDA Fast Track status for ovarian cancer, showing promising Phase I results.
- Debiopharm to Unveil New Pre-Clinical and Clinical Research Advances in DDR Inhibition, Dual Payload ADCs, and AI-Driven Biomarkers at AACR 2026
Debiopharm is presenting new clinical data on DDR inhibitors, dual payload ADC technology, and AI-driven biomarkers at the AACR 2026 meeting.
- 2026 as an Implementation Year for AI in Drug Development
Debiopharm is shifting AI from experimental pilots to core operational implementation to accelerate clinical trials and improve drug development efficiency.
- Veeva Systems Inc. acquired Yonalink Ltd. from Debiopharm Innovation Fund SA and other shareholders.
Veeva Systems Inc. completed the acquisition of Yonalink Ltd. from Debiopharm Innovation Fund SA.
- GARDP and Debiopharm Partner to Advance Antibiotic for Drug-Resistant Gonorrhea
A new partnership with GARDP aims to advance Debiopharm's novel antibiotic candidate for treating multidrug-resistant gonorrhea globally.
- GARDP und Debiopharm gehen Partnerschaft zur Förderung der Entwicklung eines neuartigen Medikaments gegen Gonorrhoe ein.
GARDP and Debiopharm are collaborating to develop and ensure global access to Debio1453, a new antibiotic, to combat drug-resistant gonorrhea.
- GARDP, Debiopharm Partner to Develop Novel Gonorrhea Drug
Debiopharm is partnering with GARDP to develop a novel antibiotic for the treatment of drug-resistant gonorrhea.
- GARDP, Debiopharm to collaborate on new gonorrhea antibiotic
A collaboration to develop a novel antibiotic for multidrug-resistant gonorrhea and expand global treatment access.
- Debiopharm Deploys Genialis Software to Advance AI-Based Biomarker Discovery
Debiopharm is implementing Genialis Expressions software to standardize multiomics data processing and accelerate AI-based biomarker discovery for its drug development programs.
- Debiopharm Deploys Genialis Software to Advance AI-Based Biomarker Discovery
Debiopharm is implementing Genialis Expressions software to standardize multiomics data and improve AI-based biomarker discovery.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Debiopharm?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies